Although the pharmaceutical market is continuing to witness global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market, such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy. Companies are considering various strategies to overcome these challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.
Small companies that primarily carry out early-stage research, development and production activities are entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence. Additionally, many companies have successfully implemented deal-making strategies to secure extended protection for their products from generic competitors. Deal activity can help pharma companies to enhance their research and regulatory approaches, and can aid portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization, and sales.
This report analyzes the importance of deal making in the pharmaceutical and healthcare market. It covers key factors that encourage deal activity in the pharmaceutical industry, and the key strategies being implemented when companies strike deals. An overview of recent deal activity from 2010 to May 2017 is also included.
What deal making strategies have been used in recent years to boost R&D productivity and allow the successful commercialization of pharmaceutical products?
In which geographical markets and disease areas has deal activity been focused since 2010?
At which stage of development did deals most frequently occur, and attract the highest value?
How have pharma companies been using deal making to strengthen their product portfolio and bottom line?
What are the most significant Mergers and Acquisitions (M&As), licensing deals and partnership deals to have been announced since 2016?
Who are the major players in pharmaceutical deal making, and what has been their recent and key deal activity?
Reasons To Buy
Gain a comprehensive understanding of the most recent healthcare deal trends.
Understand the most significant M&As, licensing deals and partnerships to have occurred in recent years.
Comprehensively analyze the trends of deal activity from 2010 to May 2017, with respect to aggregate deal value, geography, and the therapy area and stage of development of the products involved.
Understand the deal-making strategies that have been historically implemented by companies, and identify the most suitable strategies for boosting R&D portfolio and bottom line performance.
Identify the key deal terminations that have occurred in recent years, and understand their effect.
Table of Contents
Factors Promoting Deal Activity
Key Strategies Implemented in Deals
Improving Research and Development
Product Lifecycle management
Entry into Rare disease Markets
Mergers and Acquisitions (M&As)
Key Announced Deals in M&As
Key Asset Swaps
Key Announced Deals
Key Announced Deals
Terminated Licensing deals
Overview of Pharmaceutical Deals from 2010 to 2016
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry.
The re ...Read More
The Global Dental Laboratory Handpieces Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Dental Laboratory Handpieces market.
First, the report ...Read More
Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dys ...Read More
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain ...Read More
Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare a ...Read More
The hematological disorders therapy area encompasses non-malignant disorders of the blood such as anemia, sickle cell disease, neutropenia and hemophilia. These diseases can be grouped into the three ...Read More
Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapi ...Read More
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a ...Read More
Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or a ...Read More
Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation ...Read More
Published By : GBI Research
For support please contact: US Toll Free
+1 888-789-6604 Asia Pacific
To receive alerts about an update, future offers and discounts on this report, signup here. Email ID